Table 1.
Baseline characteristicsa in those receiving combination therapy with an α-blocker plus an antimuscarinic
| Overall population (N = 1891)b |
FDC (N = 665) | Concomitant therapy (N = 1226) | |
|---|---|---|---|
| Age at index date, mean (SD) | 71.95 (9.55) | 70.46 (9.11) | 72.77 (9.68) |
| Age at index date, N (%) | |||
| 45–64 years | 417 (22.1) | 172 (25.9) | 245 (20.0) |
| 65–74 years | 654 (34.6) | 260 (39.1) | 394 (32.1) |
| ≥75 years | 820 (43.4) | 233 (35.0) | 587 (47.9) |
| Polypharmacy,c mean (SD) | 3.38 (3.33) | 4.35 (3.18) | 5.54 (3.40) |
| Polypharmacy,c N (%) | |||
| 0 | 420 (22.2) | 223 (33.5) | 197 (16.1) |
| 1–3 | 729 (38.6) | 274 (41.2) | 455 (37.1) |
| 4–5 | 303 (16.0) | 79 (11.9) | 224 (18.3) |
| 6–8 | 278 (14.7) | 68 (10.2) | 210 (17.1) |
| ≥9 | 161 (8.5) | 21 (3.2) | 140 (11.4) |
| Prescriber at index date, N (%) | |||
| Urologist | 726 (38.4) | 456 (68.6) | 270 (22.0) |
| GP | 931 (49.2) | 130 (19.6) | 801 (65.3) |
| Other | 234 (12.4) | 79 (11.9) | 155 (12.6) |
| Prior treatment, N (%) | |||
| Any combination | 479 (25.3) | 230 (34.6) | 249 (20.3) |
| α-blocker + antimuscarinic | 298 (15.8) | 121 (18.2) | 177 (14.4) |
| α-blocker | 1668 (88.2) | 549 (82.6) | 1119 (91.3) |
| Antimuscarinic | 989 (52.3) | 237 (35.6) | 752 (61.3) |
| 5-ARI | 157 (8.3) | 88 (13.2) | 69 (5.6) |
| Concomitant therapy, N (%) | |||
| Both drugs initiated on the same date | – | – | 341 (27.8) |
| Both drugs initiated within 30 days | – | – | 885 (72.2) |
5-ARI 5α-reductase inhibitor, FDC fixed-dose combination, GP general practitioner, SD standard deviation
aAt index date
bThe overall population comprised men receiving FDC or concomitant therapy of an α-blocker and an antimuscarinic
cNumber of drugs (classified by Anatomical Therapeutic Chemical code) prescribed, excluding those approved for the treatment of LUTS/BPH.